Identification of the serotypes of bacterial meningitis agents; implication for vaccine usage
Abstract
Background and Objectives: Bacterial meningitis is one of the most serious infections and should be treated as emergency. As it has significant morbidity and mortality throughout the world, every country should have precise information regarding the etiological agents of disease and populations at risk to design public health prevention strategy. In the present study in addition of evaluation of common etiological agents (Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae) in bacterial meningitis cases, we sero-grouped or serotyped the obtained agents in order to predict the usefulness of existing vaccines against bacterial meningitis.
Materials and Methods: Cerebrospinal fluid of 182 suspected meningitis patients were collected, from which 114 cases were approved by biochemical, microbiological and molecular tests as bacterial meningitis. The isolated bacteria were serogrouped or serotyped to determine the dominant serotypes.
Results: Streptococcus pneumoniae accounted for 36%, Haemophilus influenza for 26% and Neisseria meningitidis for 14% of cases. From 13 serogroups of N. meningitides, the most frequent serogroups, were meningococcus group B (51%), C(24%) A (18%), Z(2%), W135 (1%) and 3% was not identified. In H. influenzae group only serotype b (100%) have been identified and in pneumococcal meningitis the most common serotype among our cases were 18C (44%) followed by14 (17%), 19A (13%), 6A (9%), 7F (4%), 4(3%), 3 (3%), 9V (2%), 8 (2%), 23f (2%), 5(1%).
Conclusion: Since there is no nationwide mass immunization program for common agents of bacterial meningitis in Iran, the result of this study can be used to improve the existing vaccines to cover the detected serotypes and consequently reduce the incidence of bacterial meningitis.
Scheld WM, Koedel U, Nathan B, Pfister HW.Pathophysiology of bacterial meningitis: mechanism(s)of neuronal injury. J Infect Dis 2002; 186 Suppl 2:S225-233.
Osrin D, Vergnano S, Costello A. Serious bacterial infections in newborn infants in developing countries. Curr Opin Infect Dis 2004; 17:217-224.
Grimwood K, Anderson VA, Bond L, Catroppa C, Hore RL, Keir EH, et al. Adverse outcomes of bacterial meningitis in school-age survivors. Pediatrics 1995;95:646-656.
WHO (2012) Bacterial meningitis. www.who.int/nuvi/meningitis.
Tunkel AR. Clinical Trials Report. Curr Infect Dis Rep 2001; 3:347-351.
Laving AM, Musoke RN, Wasunna AO, Revathi G.Neonatal bacterial meningitis at the newborn unit of Kenyatta National Hospital. East Afr Med J 2003;80:456-462.
Stoll BJ, Hansen N, Fanaroff AA, Lemons JA.Enterobacter sakazakii is a rare cause of neonatal septicemia or meningitis in VLBW infants. J Pediatr 2004; 144:821-823.
Etuwewe O, Kulshrestha R, Sangra M, Riordan A.Brain abscesses due to Citrobacter koseri in a pair of twins. Pediatr Infect Dis J 2009; 28:1035.
Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970-976.
Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004;23:S274-279.
Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20 Suppl 1:S58-67.
Dawson KG, Emerson JC, Burns JL. Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J 1999; 18:816-822.
Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-367.
Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1-28.
University health service. Bacterial Meningitis Vaccination Requirement 2013 http://www.healthyhorns.utexas.edu/requiredvaccine/
Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlow E, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 2007;13:920-923.
WHO.int/CSR (2003) MeningGAR. www.who.int/csr/resources/publications/.../MeningGAR_2003_10.pdf
Ahmed QA, Arabi YM, Memish ZA. Health risks at the Hajj. Lancet 2006; 367:1008-1015.
Davies EG, Elliman D, Hart AC, Nicoll A, Rudd P.Manual of childhood infections for the royal college of paediatrics and child health. W.B. Saunders (London)2001; paper back, 514 pages.
McVernon J, Trotter CL, Slack MP, Ramsay ME.Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004; 329:655-658.
McVernon J, Howard AJ, Slack MP, Ramsay ME. Long- term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect 2004; 132:765-767.
Wardlaw TM JE, Hodge M .Pneumonia: the forgotten killer of children. pp. 40: World Health Organization; UNICEF; 2006:40.
Park IH, Pritchard DG, Cartee R, BrandaoA, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007; 45:1225-1233.
O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria- Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902.
Boisier P, Mainassara HB, Sidikou F, Djibo S, Kairo KK, Chanteau S. Case-fatality ratio of bacterial meningitis in the African meningitis belt: we can do better. Vaccine 2007; 25 Suppl 1:A24-29.
Shields B. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. J Pediatr Health Care 2001; 15:203-208; quiz 209-210.
Segal S, Pollard AJ. Vaccines against bacterial meningitis. Br Med Bull 2004; 72:65-81.
Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob 2004; 3:3.
Tehran University of Medical Science protocols (1389) Guideline of Meningitis surveillance. http://health.tums. ac.ir/fa/620.aspx.
Nakhjavani FAH, F. Bonakdar Kalani, M. T. Kazemi, B. Detection of Type B in cerebrospinal fluid of suspected children with meningitis by PCR. Medical Journal of The Islamic Republic of Iran 2005; 19.
Brooks G, Caroll K, Butel J, Morse SA, Mietzner TA.Jawetz Melnick&Adelbergs Medical Microbiology 26/E edn.The McGraw-Hill Companies,Inc.N.Y 2013.
Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes ofStreptococcus pneumoniae isolates. J Clin Microbiol 2006; 44:124-131.
Aspa J, Rajas O, Rodriguez de Castro F, Blanquer J, Zalacain R, Fenoll A, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004; 38:787-798.
Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360:244-256.
Davis S, Feikin D, Johnson HL. The effect of Haemophilus influenzae type B and pneumococcal conjugate vaccines on childhood meningitis mortality: a systematic review. BMC Public Health 2013; 13 Suppl 3:S21.
Mehrabi Tavana A, Ataee RA. Invasive pneumococcal dsease (IPD) serotype frequency in Iranian patients. Iran Red Crescent Med J 2013; 15:740-742.
Mosavi-Jarrahi A, Esteghamati A, Asgari F, Heidarnia M, Mousavi-Jarrahi Y, Goya M. Temporal analysis of the incidence of meningitis in the Tehran metropolitan area, 1999-2005. Popul Health Metr 2009; 7:19.
Tavana AM AR. Meningococcal meningitis control in Iran: five year comparative study 2000-2004. J Med Sci 2009; 9:51-54.
Mehrabi Tavana A, Hosseini- Shokoh MJ, Gouya M, Mahmmodi Farahani M; Parhisgar SH; MD,Ansari M; MSc. The effects of vaccination against Meningococcal meningitis in Islamic Republic of Iran Military Forces during the years 1981 to 2009. JAUMS 2010; 8:186-192.
Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine; 29:9127-9131.
Zaidi AK, Khan H, Lasi R, Mahesar W. Surveillance of pneumococcal meningitis among children in Sindh, southern Pakistan. Clin Infect Dis 2009; 48 Suppl 2:S129-135.
Falade AG, Lagunju IA, Bakare RA, Odekanmi AA, Adegbola RA. Invasive pneumococcal disease in children aged <5 years admitted to 3 urban hospitals in Ibadan, Nigeria. Clin Infect Dis 2009; 48 Suppl 2:S190-196.
| Files | ||
| Issue | Vol 6 No 4 (2014) | |
| Section | Articles | |
| Keywords | ||
| Bocterial meningitis Huemophilus inflhenzae Neisseria meningitids Streptococcus pneumoniae Vaccine | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
